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Monocytes/Macrophages䌤
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Although oral coinfections (e.g., periodontal disease) are highly prevalent in human immunodeficiency virus
type 1-positive (HIV-1ⴙ) patients and appear to positively correlate with viral load levels, the potential for oral
bacteria to induce HIV-1 reactivation in latently infected cells has received little attention. We showed that
HIV-1 long terminal repeat (LTR) promoter activation can be induced by periodontopathogens in monocytes/
macrophages; nevertheless, the mechanisms involved in this response remain undetermined. Since Toll-like
receptor 2 (TLR2), TLR4, and TLR9 activation have been involved in HIV-1 recrudescence, we sought to
determine the role of these TLRs in HIV-1 reactivation induced by the periodontal pathogens Fusobacterium
nucleatum and Porphyromonas gingivalis using BF24 monocytes/macrophages stably transfected with the HIV-1
promoter driving chloramphenicol acetyltransferase (CAT) expression and THP89GFP cells, a model of HIV-1
latency. We demonstrated that TLR9 activation by F. nucleatum and TLR2 activation by both bacteria appear
to be involved in HIV-1 reactivation; however, TLR4 activation had no effect. Moreover, the autocrine activity
of tumor necrosis factor alpha (TNF-␣) but not interleukin-1␤ (IL-1␤) produced in response to bacteria could
impact viral reactivation. The transcription factors NF-B and Sp1 appear to be positively regulating HIV-1
reactivation induced by these oral pathogens. These results suggest that oral Gram-negative bacteria (F.
nucleatum and P. gingivalis) associated with oral and systemic chronic inflammatory disorders enhance HIV-1
reactivation in monocytes/macrophages through TLR2 and TLR9 activation in a mechanism that appears to
be transcriptionally regulated. Increased bacterial growth and emergence of these bacteria or their products
accompanying chronic oral inflammatory diseases could be risk modifiers for viral replication, systemic
immune activation, and AIDS progression in HIV-1ⴙ patients.
with chronic immune activation in HIV-1⫹ patients and AIDS
progression, even in the presence of highly active antiretroviral
therapy (HAART) (10, 41, 69).
The cellular and molecular mechanisms by which opportunistic commensal and pathogenic microorganisms could enhance HIV reactivation in latently infected cells remain somewhat unclear; however, growing evidence suggests a role for
Toll-like receptors (TLRs) and various signaling molecules and
transcription factors involved in TLR activation. To date, HIV
reactivation associated with TLR2, TLR4, and TLR9 has been
shown with different cell types (22, 23). Nevertheless, Nordone
et al. in a recent study found that TLR4 stimulation did not
induce HIV production, by using an ultrapurified LPS from
Escherichia coli (57). In addition to TLR agonists, soluble
factors and proinflammatory cytokines (e.g., tumor necrosis
factor alpha [TNF-␣]) produced in response to bacterial challenge could also be involved in HIV-1 reactivation acting in an
autocrine manner (6, 32, 46). Normally both TLRs and cytokine receptors activate transcription factors downstream (e.g.,
NF-B, AP-1, Sp1, etc.) that not only will turn on proinflammatory cytokine/chemokine genes but also could activate the
HIV-1 promoter, which also has consensus binding sequences
for them (42, 60). Particularly, NF-B is considered a positive
regulator of proviral reactivation in latently infected cells; however, its upregulation alone may not be sufficient to activate the
HIV promoter (57, 75). On the other hand, the role of Sp1

AIDS is caused by the retrovirus human immunodeficiency
virus type 1 (HIV-1), which targets immune cells, such as
CD4⫹ T cells, monocytes, macrophages, and dendritic cells
(67). After a few weeks of HIV-1 infection, a massive CD4⫹
T-cell depletion occurs mainly at mucosal surfaces, and viral
reservoirs (i.e., latently infected cells) are formed (11, 29).
Although CD4⫹ T cells are the most stable and well-characterized viral reservoir, monocytes/macrophages have received
particular attention because they, unlike CD4⫹ T cells that are
depleted by apoptosis during AIDS, exhibit a resistance to
virus-mediated apoptotic death. This promotes a long-term
persistence of the HIV infection and a potential contribution
to development of the immunodeficiency symptoms. In addition to being a critical viral reservoir, infected monocytic cells
may also transfer HIV to uninfected T cells (73). Although the
mechanisms associated with AIDS progression are not fully
understood, it has been shown that active production of HIV-1
proteins (i.e., Tat, Nef, and Vpr) during viral replication and
bacterial translocation of coinfecting non-HIV-1 pathogens or
their products, such as lipopolysaccharide (LPS) and DNA
from mucosal surfaces, appear to be critical factors associated
* Corresponding author. Mailing address: Center for Oral Health
Research, College of Dentistry, University of Kentucky, 1095 VA
Drive, HSRB 414, Lexington, KY 40536-0305. Phone: (859) 323-0045.
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MATERIALS AND METHODS
Bacterial strains and growth conditions. The bacterial strains used in this
study were Porphyromonas gingivalis (ATCC 33277) grown in anaerobic broth
(Becton Dickinson, Sparks, MD), and Fusobacterium nucleatum (ATCC 25586)
grown in Trypticase soy broth supplemented with yeast extract (TSBYE). Bacterial cultures were grown at 37°C under anaerobic conditions (80% N2, 10% H2,
and 10% CO2) as described previously (31, 39, 44). Bacterial extracts were
obtained starting with 5 colonies grown on CDC anaerobic 5% sheep blood agar
plates (Remel, Lenexa, KS), which were further placed into 25 ml of corresponding broth and incubated for 24 h. Then, bacterial cultures were transferred into
500 ml of corresponding broth and incubated under the same conditions for 24 h.
The bacterial suspension was washed three times with sterile phosphate-buffered
saline (PBS) and centrifuged at 10,000 ⫻ g for 20 min at 4°C. The pellet was
reconstituted in 15 ml of PBS with complete EDTA-free protease inhibitor

cocktail (Roche, Mannheim, Germany), followed by sonication of the bacterial
pellet using an ultrasonic disrupter (Branson Sonifier model 450; Branson, Danbury, CT). Disruption of bacteria was confirmed by light microscopy. The crude
extract after sonication was centrifuged at 13,000 ⫻ g for 10 min at 4°C, and
supernatants were evaluated for protein concentration by a bicinchoninic acid
(BCA) assay (Pierce, Rockford, IL) and used to challenge BF24 and THP89GFP
cells in concentrations between 1 and 10 g/ml of protein.
Cell cultures. BF24 cells were obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, NIH, from Barbara K.
Felber and George N. Paviakis (25). The BF24 cell line is a subclone of the
monocytic leukemia cell line THP-1 that was stably transfected with the HIV-1
long terminal repeat (LTR) promoter driving the chloramphenicol acetyltransferase (CAT) reporter gene expression. THP89GFP cells were a generous gift of
David Levy (New York University). These cells were infected with an HIV-1
virus that expresses the enhanced green fluorescent protein (EGFP) under the
control of the HIV-1 promoter without removing any viral sequences. Fluorescence and virus production are tightly coupled in THP89GFP cells (49). Parental
THP-1 cells were used as a negative control for analyses of EGFP expression by
flow cytometry. All cell types were cultured in RPMI 1640 with L-glutamine and
10% fetal bovine serum (FBS) and maintained in a 5% CO2 atmosphere at 37°C.
In addition, 100 U/ml penicillin and 100 g/ml streptomycin were used for
THP89GFP cultures.
DNA isolation from oral bacteria. Bacterial DNA was isolated using the
Wizard Genomic DNA purification kit (Promega, Madison, WI) according to the
manufacturer’s instructions. Briefly, 600 l of bacteria (109 cells/ml) resuspended
in 50 mM EDTA were centrifuged at 1,000 ⫻ g for 2 min at room temperature.
Further, 600 l of lysis buffer was added into the pellets, and cells were incubated
at 80°C for 5 min. Then, RNA and protein were removed by incubation with 3 l
RNase followed by treatment with 200 l of protein precipitation solution. After
centrifugation at 10,000 ⫻ g for 3 min, DNA-containing supernatants were
transferred and mixed with isopropanol to precipitate the bacterial DNA. Finally, DNA-containing pellets were obtained by centrifugation at 10,000 ⫻ g for
2 min and washed once with 70% ethanol. Bacterial DNA was resuspended in 50
l of endotoxin-free water, and the DNA concentration was obtained using the
spectrophotometer and software Nanodrop (ND-1000) (Thermo Scientific, Wilmington, DE).
Stimulation of cells with bacterial extracts and TLR agonists. Monocytes/
macrophages were seeded in 24-well plates at a cell density of 2.5 ⫻ 105 cells/well
in 1 ml of RPMI 1640 medium supplemented with 2% FBS and incubated 16 h
either with media alone or in the presence of different concentrations of each
bacterial extract (1 to 10 g/ml) obtained as described above and purified
lipopolysaccharide (LPS) (1 to 100 ng/ml) from E. coli 0111:B4 (TLR4 agonist)
and P. gingivalis (TLR2 agonist) or CpG ODN2006 (TLR9 agonist) (InvivoGen,
San Diego, CA). The bacterial extract concentrations used to stimulate the cells
are representative of a cell/bacterium ratio range of 1:10 to 1:100. Unstimulated
cells were used as a negative control. For neutralization assays, cells were preincubated 1 h with the monoclonal antibody mouse IgG2a anti-human TLR2,
mouse IgG1 anti-human TNF-␣, and anti-human interleukin 1␤ (IL-1␤) with
their correspondent isotype controls (eBioscience and BD Pharmingen, San
Diego, CA), or inhibitory oligodeoxynucleotide (ODN) TTAGGG (InvivoGen,
San Diego, CA) before challenge with bacterial extracts or TLR agonists. Chloroquine (Sigma, St. Louis, MO), as well as enzymatic pretreatment of bacterial
DNA from F. nucleatum with 5 U DNase or RNase for 1 h at 37°C followed by
inactivation at 65°C for 15 min, was also used to inhibit TLR9 activation as
previously shown (24, 53).
HIV-1/CAT ELISA. HIV-1 LTR CAT activation was measured by a sandwich
enzyme-linked immunosorbent assay (ELISA) using a commercially available kit
(Roche, Mannheim, Germany). Briefly, BF24 cells were harvested after several
treatments and washed with 1⫻ PBS at 2,600 ⫻ g for 15 min. Then, pellets were
resuspended in 220 l lysis buffer provided in the kit for 30 min at room
temperature (RT). Further, 210 l of lysed cells were placed in 96-well plates
precoated with an anti-chloramphenicol acetyltransferase (anti-CAT) for 2 h at
37°C. After washing, a primary antibody anti-CAT conjugated with digoxigenin
(anti-CAT-DIG) was added for 1 h, followed by a secondary antibody antidigoxigenin conjugated with peroxidase (anti-DIG-POD). Finally, the reaction
was revealed using 200 l/well of ABTS [2,2⬘-azinobis(3-ethylbenzthiazolinesulfonic acid)] substrate for 40 min at RT. The absorbance was measured using a
SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA) at 405 nm.
Detection of p24 by ELISA. Supernatants from THP89GFP cells were harvested after different treatments and evaluated for the presence of HIV-1 p24
protein by ELISA using a commercially available kit (Advanced BioScience
Laboratories, Inc., Kensington, MD). The manufacturer’s instructions were fol-
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remains controversial since both positive and negative regulation of the HIV-1 promoter by this transcription factor has
been reported mainly in T cells (40, 51, 68, 76). Whether or not
Sp1 is involved in TLR-induced HIV-1 reactivation in monocyte and macrophage cells remains unclear.
Similarly to the gut, the oral cavity is colonized by a high
number and variety of microorganisms that upon immunosuppression caused by HIV-1 infection will grow and cause disease. In fact, a high prevalence of oral bacterial (e.g., HIV-1
gingivitis and periodontitis), fungal (e.g., pseudomembranous
candidiasis), and viral (e.g., oral hairy leukoplakia and Kaposi’s
sarcoma) coinfections in HIV-1⫹ patients has been described
widely (18, 55). Evidence also suggests that periodontal disease, oral candidiasis, and oral hairy leukoplakia positively
correlate with higher HIV viral loads (1, 2, 15, 28, 59), although
the potential for oral pathogens to stimulate latently infected
cells and induce HIV-1 reactivation has received little attention (27). We have recently shown using gene reporter assays
that periodontal pathogens have the capacity to differentially
enhance HIV-1 promoter activation in T cells, monocytes,
macrophages, and dendritic cells in vitro (35). In addition, a
recent study showed that the bacterial metabolic product butyric acid, which can be produced by various oral Gram-negative bacteria, including Porphyromonas gingivalis, has the ability
to induce HIV-1 replication in latently infected T cells, monocytes, and macrophages through histone deacetylase inhibition.
Furthermore, the same group reported that stimulation with
isolated LPS or fimbria (TLR2 agonists) from Porphyromonas
gingivalis did not induce HIV-1 reactivation (36). Thus, the
potential of TLR activation by engagement of oral pathogens
to induce HIV-1 reactivation remains undetermined. Herein
we demonstrate that oral Gram-negative bacteria (Fusobacterium nucleatum and P. gingivalis) associated with oral (i.e.,
periodontal disease) and systemic (i.e., atherosclerosis and diabetes) chronic inflammatory disorders (26, 52) have the ability to induce HIV-1 reactivation in monocytes/macrophages
through TLR2 and TLR9 activation. Importantly, in spite of a
reduced TNF-␣ production by virally infected cells (i.e.,
THP89GFP) in response to bacteria, TNF-␣ appears to play a
critical role in this response. Lastly, HIV-1 reactivation appears to be positively regulated by NF-B and Sp1 transcription factors. These results suggest that a fine balance of signaling pathways and transcription factors activated by these
TLRs along with other receptors (e.g., cytokine receptors)
could be critical in defining either HIV-1 reactivation or maintenance of latency in HIV-1-chronically infected monocytes/
macrophages exposed to these periodontal pathogens.

CLIN. VACCINE IMMUNOL.

VOL. 17, 2010

HIV-1 REACTIVATION BY PERIODONTOPATHOGENS

RESULTS
Periodontal pathogens F. nucleatum and P. gingivalis induce
HIV-1 promoter activation in monocytes/macrophages. The
abilities of several opportunistic and pathogenic microorganisms (i.e., Mycobacterium tuberculosis, Streptococcus pneumoniae, and Neisseria gonorrhoeae) commonly found during
HIV-1 infections to directly induce HIV-1 reactivation in latently infected cells have previously been shown (7, 12, 16);
however, the potential impact of oral microorganisms associated with highly prevalent oral chronic infectious diseases in
HIV-1⫹ patients in HIV-1 exacerbation remains undetermined. Herein, we evaluated the ability of two pathogens associated with oral and systemic chronic inflammatory disorders
to induce HIV-1 promoter activation in monocytes/macrophages. Both extracts from P. gingivalis and F. nucleatum induced HIV-1 LTR CAT promoter activation in a dose-dependent manner in BF24 cells (Fig. 1A). Consistently with these
results, HIV-1 reactivation in THP89GFP cells examined by
fluorescence microscopy was remarkably upregulated by oral

Gram-negative bacteria compared with unstimulated cells
(Fig. 1B). Quantitative analyses by FACS showed that about 80
to 90% of the total cell population exhibited HIV-1/EGFP
promoter activation compared with 10% of unstimulated cells
after treatment with bacterial extracts (Fig. 1C), which correlated with the HIV-1 promoter activation determined as mean
fluorescence intensity by FACS (Fig. 1D).
Effect of TLR2, TLR4, and TLR9 activation on HIV-1 promoter activation in monocytes/macrophages. As mentioned
earlier, an important mechanism by which mammalian cells
recognize bacteria is mediated by evolutionary, highly conserved receptors named pattern recognition receptors (PRRs),
including Toll-like receptors (TLRs) and nucleotide oligomerization domain (Nod)-like receptors that promote downstream
activation of transcription factors (i.e., NF-B, Sp1, CREB,
and C/EBP), which generally regulate the production of several proinflammatory mediators (5). Given that the HIV-1
promoter harbors binding sequences for these transcription
factors, it has been suggested that TLR activation could be
involved in HIV-1 reactivation from latently infected cells (60,
63). Attempting to determine the role of TLRs in HIV-1 promoter activation, BF24 cells were first tested for their ability to
respond to purified TLR2, TLR4, and TLR9 agonists, and
HIV-1 LTR CAT was further determined. Although all TLR
agonists enhanced IL-8 production (Fig. 2), only CpG 2006
(TLR9) and LPS from P. gingivalis (TLR2) at higher concentrations (100 ng/ml), but not E. coli (TLR4), induced HIV-1
promoter activation (Fig. 2). Based on these results and the
natural ability of bacterial DNA to activate TLR9, the HIV-1
promoter activity was further evaluated in cells exposed to
isolated DNA from F. nucleatum and P. gingivalis. The bacterial DNA concentrations obtained were 343 g/ml for P. gingivalis and 1,006 g/ml for F. nucleatum with purity (A260/A280
ratio) between 1.95 and 2.12. The higher bacterial extract concentrations (10 g/ml) had DNA levels between 2 and 10
g/ml, a range of DNA concentrations that was used to challenge BF24 cells. Only DNA from F. nucleatum, but not P.
gingivalis, activated the HIV-1 promoter; however, consistently
with the previous results, the whole bacterial extracts from
both periodontal pathogens increased HIV-1 LTR activity
(Fig. 3A). Preincubation of BF24 cells with the TLR9 inhibitor
chloroquine before challenge with DNA from F. nucleatum
reduced the HIV-1 LTR activation (Fig. 3B). A similar effect
was observed when BF24 cells were preincubated with the
inhibitory CpG TTAGGG (data not shown).
Similarly, when THP89GFP cells were stimulated with DNA
from F. nucleatum, HIV-1/EGFP activity and viral replication
were upregulated in a dose-dependent manner determined by
fluorometry and ELISA (Fig. 3C). Both HIV-1/EGFP promoter activity and viral replication determined by p24 levels in
supernatants were reduced when DNA from F. nucleatum was
pretreated with DNase but not RNase (Fig. 3D).
To better rule out the potential role for TLR2 activation by
P. gingivalis and F. nucleatum in HIV-1 promoter activity, we
determined the HIV-1 promoter activity induced by the whole
extract of these periodontal pathogens in monocytes/macrophages preincubated with monoclonal anti-TLR2 or its correspondent isotype control. Neutralization of TLR2 reduced by
50% the HIV-1 promoter activity induced by the F. nucleatum
extract in BF24 cells (Fig. 4A), while the response induced by
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lowed, and absorbance was measured using a SpectraMax M2 plate reader
(Molecular Devices, Sunnyvale, CA) at 450 nm.
Fluorescence microscopy. THP89GFP cells were photographed in culture
through a Nikon Eclipse TS100 inverted microscope using ⫻100 magnification
with a QICAM Fast1394 device camera (QImaging, Surrey, BC, Canada). To
detect EGFP fluorescence, the 495-nm green fluorescent protein filter set was
used.
Flow cytometry analysis. Flow cytometry analysis was performed with a
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). After different
treatments, THP89GFP cells were harvested, washed with 1⫻ PBS at 1,300 ⫻ g
for 5 min, and fixed with 2% paraformaldehyde solution for 20 min before
fluorescence-activated cell sorter (FACS) analysis.
Fluorometry. After different treatments, THP89GFP cells were harvested and
washed in 1⫻ PBS at 1,300 ⫻ g for 5 min. Further, pellets were resuspended in
150 l of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P-40) for 20
min on ice. Then, cell lysates were centrifuged at 10,000 ⫻ g for 5 min at 4°C, and
100 l of supernatants was added into Optilux 96-well clear-bottom plates (BD
Falcon, Franklyn Lakes, NJ) for fluorescence analysis using the microplate fluorescence reader FLx800 (Bio-Tek Instruments, Inc., Winooski, VT). The wavelengths used for excitation and emission were 485 nm and 528 nm, respectively.
Analysis of cytokine production. Supernatants from cell cultures were harvested after different treatments and centrifuged at 2,600 ⫻ g, 4°C for 10 min.
Further supernatants were evaluated for the presence of TNF-␣, IL-1␤, IL-6
(eBioscience, San Diego, CA), and IL-8 (R&D Systems, Minneapolis, MN) using
commercially available ELISA kits and following the manufacturer’s instructions. The reaction was revealed by adding substrate solution at RT, and absorbance was measured using a SpectraMax M2 plate reader (Molecular Devices,
Sunnyvale, CA) at 450 nm.
Transcription factor analysis. To determine the role of transcription factors in
HIV-1 reactivation induced by bacteria, cells were challenged with 10 g/ml of
bacterial extracts in the presence of different concentrations of the specific
NF-B transcription factor inhibitor BAY 11-7082 (Calbiochem, San Diego, CA)
dissolved in dimethyl sulfoxide (DMSO). In addition, THP89GFP cells transfected with either Sp1 small interfering RNA (siRNA) or a nonsilencing (NS)
siRNA (Qiagen Sciences, Germantown, MD) were used to determine the role of
Sp1 in bacterium-induced HIV-1 reactivation. Briefly, 1 ⫻ 105 cells/well were
seeded in 6-well plates with 1.6 ml RPMI 1640 supplemented with 10% FBS
overnight. Then, cells were transfected with 2 M siRNA using DharmaFECT 2
(Dharmacon, Chicago, IL). Sp1 silencing was confirmed by Western blotting
using the monoclonal antibodies mouse IgG1 anti-Sp1 and anti-␤-actin (Santa
Cruz Biotechnology, Santa Cruz, CA). THP89GFP cells were exposed to bacterial extracts 48 h after transfection, and HIV-1/EGFP levels in cell lysates as well
as p24 levels in supernatants were determined 48 h later by fluorometry and
ELISA, respectively, as described previously.
Statistical analysis. The significance of any difference between the means for
the experimental groups was determined by Student’s t test. The means were
considered significantly different if P was ⱕ0.01.
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the P. gingivalis extract was nearly completely abrogated (approximately 90%), compared with cells preincubated with the
correspondent isotype control (Fig. 4B). Furthermore, neutralization of TLR2 in THP89GFP cells reduced the HIV-1/EGFP
and p24 levels induced by P. gingivalis (Fig. 4C); however,
TLR2 blocking was less efficient for reducing bacterium-induced HIV-1 reactivation in virally infected THP89GFP cells
compared with the effect of blocking TLR2 previously observed with BF24 cells. In contrast, the presence of anti-TLR2
in THP89GFP cells challenged with F. nucleatum did not affect
HIV-1/EGFP levels or p24 production compared with cells
incubated with the isotype control (Fig. 4C).
TNF-␣ produced in response to F. nucleatum and P. gingivalis is involved in HIV-1 promoter activation. Normally, the
activation of TLRs in monocytes/macrophages by bacteria
leads to the production of proinflammatory cytokines (e.g.,
TNF-␣, IL-1␤, and IL-6). Importantly, these proinflammatory
cytokines have been suggested as an important mechanism of
HIV-1 reactivation in latently infected cells (20, 61). Hence, to
test whether production of these cytokines in response to F.
nucleatum and P. gingivalis was playing a role in HIV-1 promoter activation, we first determined the levels of TNF-␣,
IL-1␤, and IL-6 produced by either THP89GFP cells or their
parental THP-1 cells in response to different concentrations of
bacterial extracts. Although detectable levels of all proinflam-

matory cytokines were observed with supernatants from
THP-1 parental cells, only TNF-␣ and IL-1␤, not IL-6, were
detected in supernatants from virally infected THP89GFP cells
exposed to bacterial extracts. Of note, the levels of TNF-␣ and
IL-1␤ produced by THP89GFP cells in response to bacterial
extracts were significantly lower (5- to 15-fold) compared with
the cytokine levels produced by THP-1 parental cells (data not
shown). Further, in order to determine the potential for
TNF-␣ and IL-1␤ produced in response to bacterial extracts to
enhance HIV-1/EGFP promoter activity in THP89GFP cells,
neutralization assays using monoclonal antibodies against
these cytokines or correspondent isotype controls were performed. Neutralization of TNF-␣ reduced by about 40 to 50%
the HIV-1/EGFP promoter activation induced by F. nucleatum
and by nearly 90% the response induced by P. gingivalis compared with the effect of its correspondent isotype control (Fig.
5A and B). In contrast, neutralization of IL-1␤ did not induce
changes in bacterium-induced HIV-1/EGFP promoter activation (Fig. 5C and D).
Transcription factors NF-B and Sp1 are positive regulators of periodontal pathogen-induced HIV-1 reactivation in
monocytes/macrophages. Growing evidence suggests that upon
TLR activation several signaling pathways and transcription
factors are activated, including NF-B and Sp1, among others
(42, 58). Since both NF-B and Sp1 transcription factors have
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FIG. 1. Effect of F. nucleatum and P. gingivalis extracts on HIV-1 promoter activation in monocytes/macrophages. BF24 and THP89GFP cells
(2.5 ⫻ 105/ml) were either exposed or not (mock) to bacterium extracts. Parental THP-1 (WT) cells were used as a negative control for FACS.
(A) HIV-1 CAT promoter activation in BF24 cells challenged with several extract concentrations of each bacterium for 16 h was determined by
ELISA. (B) Induction of HIV-1/EGFP in THP89GFP monocytes/macrophages incubated with 10 g/ml bacterial extracts for 24 h was visualized
by light microscopy and fluorescence microscopy using ⫻100 magnification. Percentage of EGFP-positive cells (C) and mean fluorescence intensity
(MFI) of HIV-1/EGFP cells (D) described in the legend to panel B were quantified by flow cytometry as described in Materials and Methods. The
data are representative of two independent experiments with triplicate determinations (n ⫽ 6). Data are expressed as means ⫾ standard deviations.
ⴱ, P ⬍ 0.01 compared to the results for the control (mock), as determined by Student’s t test.
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also been shown to be important regulators of HIV-1 reactivation (38, 40), we evaluated the role of these transcription
factors in HIV-1 reactivation induced by F. nucleatum and P.
gingivalis. Monocytes/macrophages were challenged with periodontal pathogen extracts, either in the presence or absence of
the specific NF-B inhibitor BAY 11-7082. The presence of
BAY 11-7082 completely abrogated the HIV-1 LTR CAT activity induced by F. nucleatum and P. gingivalis in BF24 monocytes/macrophages; however, this response was not affected by
the solvent DMSO (Fig. 6A). Consistently, viral replication
determined by p24 levels in supernatants of THP89GFP cells
exposed to bacterial extracts was substantially blocked by the
presence of the NF-B inhibitor (Fig. 6B). Furthermore, to
determine the role of Sp1 transcription factor in bacteriuminduced HIV-1 reactivation, Sp1 protein expression was silenced by transient transfection of THP89GFP cells with specific Sp1 siRNAs. The transfection of THP89GFP cells with
two different Sp1 siRNAs significantly reduced the protein
levels of Sp1 compared with cells transfected with nonsilencing
siRNA and nontransfected cells as determined by Western
blotting (Fig. 6C). Both HIV-1/EGFP promoter activation and
viral replication induced by F. nucleatum and P. gingivalis were
significantly reduced in THP89GFP monocytes/macrophages
transfected with Sp1 siRNAs but not nonsilencing siRNA (Fig.
6D and E).
DISCUSSION
Translocation of bacterial products (e.g., LPS and DNA)
into the systemic circulation through impaired mucosal sur-

faces has been associated with HIV-1 exacerbation, chronic
immune activation, and AIDS progression (10, 41). Similarly to
the gut, the oral cavity is colonized by a wide variety and
number of microorganisms, including commensal, opportunistic, and pathogenic species (about 1 ⫻ 108 to 1 ⫻ 109 bacteria/mg of plaque) (66). Growing evidence suggests that periodontal pathogens, including F. nucleatum and P. gingivalis, or
their products can not only cause local inflammation at the oral
cavity but also appear to emerge systemically and enhance
inflammatory responses associated with conditions such as atherosclerosis, preterm birth, and diabetes (13, 21, 37, 47, 52). A
high prevalence of oral opportunistic infections, including severe forms of periodontal disease in HIV-1⫹ patients, has been
demonstrated widely (18, 48). Nevertheless, the potential for
oral pathogens to enhance HIV-1 exacerbation has received
little attention. Supporting our previous findings herein, we
show that HIV-1 promoter activity was increased significantly
when BF24 and THP89GFP monocytes/macrophages were exposed to bacterial extracts from periodontal pathogens F. nucleatum and P. gingivalis (35).
Oral bacteria, including F. nucleatum and P. gingivalis, can
activate TLR2, TLR4, and TLR9, inducing the production of
cytokines and chemokines (45, 50, 56, 71, 72), and the same
group of TLRs has been involved in HIV-1 reactivation from
latently infected cells (22, 23). Initial treatment of BF24 monocytes/macrophages with purified agonists for these TLRs
showed that only TLR9 (CpG2006) but not TLR2 (P. gingivalis
LPS) and TLR4 (E. coli and other LPS) engagement was able
to induce HIV-1 LTR activation. These findings led us further
to evaluate the HIV-1 promoter activity induced by isolated
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FIG. 2. Effect of Toll-like receptor agonists on HIV-1 CAT promoter activation in BF24 monocytes/macrophages. Cells were incubated with
either 10 g/ml bacterial extracts or different concentrations of LPS from P. gingivalis (TLR2 ligand), LPS from E. coli (TLR4 ligand), or CpG
ODN2006 (TLR9 ligand). IL-8 production in culture supernatants was analyzed by ELISA, and HIV-1 promoter activation was measured by
determination of CAT levels in cell lysates as described in Materials and Methods. The data are representative of three independent experiments
with triplicate determinations (n ⫽ 9). Data are expressed as means ⫾ standard deviations. ⴱ, P ⬍ 0.01 compared to the results for the control
(mock), as determined by Student’s t test.
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DNA from F. nucleatum and P. gingivalis as a natural TLR9
ligand. Interestingly, only DNA from F. nucleatum triggered
HIV-1 promoter activation in a dose-dependent manner. It has
been shown that differences in the abilities of DNA from different bacterial strains to activate TLR9 could be related to the
frequency of CpG motifs in the bacterial genome (19). In
effect, differences in cytokine production by monocytic cells
and gingival fibroblasts in response to DNA from P. gingivalis
and Actinobacillus actinomycetemcomitans have been associated with the frequency of CpG motifs in their genomes (56).
To the best of our knowledge there is not published evidence
addressing the effect of TLR9 activation by DNA from F.
nucleatum in monocytic cells; however, its increased ability to
trigger HIV-1 promoter activation in BF24 cells, with respect
to the effect induced by DNA from P. gingivalis, suggests that
there could be important variations in the CpG motif frequency in its genome. Since the HIV-1 promoter response
associated with TLR9 activation by bacterial DNA did not
completely recapitulate the levels of HIV-1 promoter activity
observed with the whole extract of F. nucleatum, there could be
other microbial structures involved in this response or synergism between bacterial DNA, and other TLR ligands, as well
as host cytokines, would be potentially contributing to the
magnitude of response. A recent study demonstrated that systemic levels of bacterial DNA in HIV-1⫹ patients correlated

with chronic immune activation and AIDS progression (41). F.
nucleatum is found not only in oral mucosa but also at the
urogenital level, at which it has been related to vaginosis and
undesirable pregnancy outcomes (33, 34). Of note, HIV-1 promoter activity triggered by DNA from F. nucleatum in monocytes/macrophages correlated with viral replication. Thus,
overgrowth of F. nucleatum at mucosal surfaces as well as
systemic translocation of this microorganism could increase
the risk of HIV-1 viral exacerbation, disease progression, and
perhaps viral transmission.
Early studies suggested that LPS from Gram-negative bacteria was a strong inducer of HIV-1 reactivation (22, 62).
Nevertheless, it was recently shown by Nordone et al. that LPS
from E. coli that activates TLR-4 appeared not to be involved
in HIV-1 reactivation (57). The differences in the effect of LPS
in HIV-1 promoter activation were attributed to contamination of LPS with TLR2 agonists, as well as the use of different
cell lines. In our study, stimulation of BF24 cells with LPS from
different enteric and oral bacterial strains was not sufficient to
recapitulate the HIV-1 promoter activity induced by the whole
extracts of F. nucleatum and P. gingivalis (data not shown).
These results indicate that TLR4 activation itself could not be
sufficient to trigger HIV-1 promoter activation in these latently
infected monocytic cells. It does not allow us to rule out the
potential for TLR4 activation by LPS as a potential modulator
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FIG. 3. TLR9 activation by DNA from F. nucleatum is involved in HIV-1 reactivation in monocytes andmacrophages. (A) BF24 cells were
incubated with either purified DNA or whole bacterial extracts from F. nucleatum or P. gingivalis for 16 h, and HIV-1 CAT promoter activation
in cell lysates was determined by ELISA. ND denotes “nondetected” (values below the level of detection). (B) HIV-1 CAT promoter activity
induced by 10 g/ml DNA from F. nucleatum in BF24 cells preincubated (or not) for 1 h with the TLR-9 inhibitor chloroquine. (C) Induction of
HIV-1/EGFP promoter activity in cell lysates (gray bars) and p24 levels in supernatants (black bars) by several concentrations of DNA from F.
nucleatum for 24 h was determined in THP89GFP cells by fluorometry and ELISA, respectively, as described in Materials and Methods. MCF,
mean cumulative fluorescence. (D) Effect of enzymatic pretreatment of DNA from F. nucleatum with DNase or RNase in HIV-1 reactivation after
24 h of incubation is shown. The data are representative of three independent experiments with triplicate determinations (n ⫽ 9). Data are
expressed as means ⫾ standard deviations. ⴱ, P ⬍ 0.01 compared to the results for the control (mock), as determined by Student’s t test.
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of HIV-1 promoter activation induced by other TLRs or cytokine receptors. Indeed, synergism between LPS and granulocytic macrophage and monocytic colony stimulator factor
(GM-CSF) for inducing HIV-1 reactivation was recently reported (58).
On the other hand, TLR2 activation by LPS from P. gingivalis did not increase substantially HIV-1 promoter activity;
however, previous reports have shown that stimulation with
other TLR2 agonists (e.g., Pam3CSK4) or whole bacteria (e.g.,
M. tuberculosis) induces HIV-1 reactivation in different cell
types, including monocytic cells (4, 57). The possibility of
TLR2 interacting with different bacterial structures (i.e., peptidoglycan, lipoteichoic acid, etc.) and forming heterodimers
with TLR1 and TLR6 presents the likelihood of different cellular responses, depending upon the combination of this group
of alternatives. It has been shown that LPS from P. gingivalis is
recognized by the heterodimer TLR2/TLR1, and fimbriae
from the same microorganism interact with both TLR2/TLR1
and TLR2/TLR6 heterodimers in order to induce TNF-␣ production (30). Thus, it is possible that TLR2/TLR6 activation by
fimbriae could be triggering HIV-1 promoter activation in our
system; however, Imai et al. showed that recombinant fimbriae
from P. gingivalis were not sufficient to induce HIV-1 reactivation in latently infected monocytes and T cells (36). To
confirm the lack of a role for TLR2 activation by periodontopathogens in HIV-1 promoter activation, neutralization assays
using a monoclonal anti-TLR2 were performed. Interestingly,

HIV-1 promoter activity was partially reduced by anti-TLR2 in
cells challenged with F. nucleatum, and it was virtually abrogated in cells stimulated with P. gingivalis. These results suggest
that other structural components rather than LPS or fimbriae
from P. gingivalis or F. nucleatum with affinity for TLR2 could
be involved in HIV-1 promoter activation. Nevertheless, since
a cross talk between TLRs, Nod receptors, and cytokine receptors has been suggested to be critical for the final cellular
response (70, 77), it is also likely that individual TLR2 and
TLR4 activation by isolated structural components of periodontal pathogens may not be sufficient to induce HIV-1 promoter activation, but these TLRs could synergize with other
cellular receptors in order to trigger this response.
Several in vitro and in vivo studies have shown that proinflammatory cytokines (e.g., TNF-␣, IL-1␤, IL-6, etc.) could be
playing a role in HIV-1 reactivation in latently infected cells,
including monocytes/macrophages. Moreover, increased
TNF-␣ levels in serum from HIV-1⫹ patients have been associated with HIV-1 exacerbation and disease progression (32,
74). In agreement with these observations we showed that even
though there was a substantial reduction in proinflammatory
cytokine production in HIV-1-infected cells (i.e., THP89GFP
cells), with regard to noninfected THP-1 cells, autocrine activity of TNF-␣, but not IL-1␤, produced in response to both
periodontal pathogens appears to play a critical role in HIV-1
reactivation. Importantly, the impaired cytokine production by
THP89GFP cells compared with the parental cell line, as well
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FIG. 4. Blocking of TLR2 inhibits bacterium-induced HIV-1 reactivation. Cells (2.5 ⫻ 105/ml) were preincubated for 1 h with different
concentrations of either a monoclonal anti-TLR2 neutralizing antibody or its respective isotype control before challenge with 10 g/ml of bacterial
extracts. Effect of TLR2 neutralization in HIV-1 CAT promoter activation induced by F. nucleatum (A) and P. gingivalis (B) in BF24 cells exposed
to bacteria for 16 h is shown. ␣, anti-. (C) Effects of TLR2 neutralization in HIV-1/EGFP promoter activation (gray bars) in cell lysates and p24
levels (black bars) in supernatants of THP89GFP cells exposed to bacteria for 48 h are shown. The data are representative of two independent
experiments with triplicate determinations (n ⫽ 6). Data are expressed as means ⫾ standard deviations. ⴱ, P ⬍ 0.01 compared to the results for
the cells challenged with bacteria in the presence of anti-TLR2 versus the isotype control, as determined by Student’s t test.
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as the reduced effect of anti-TLR2 in bacterium-induced
HIV-1 reactivation, with regard to BF24 cells, supports recent
findings in which HIV-1 infection altered the expression and
activation of TLRs, with a consequent reduction in cytokine
expression (54).
Finally, the presence of consensus binding sequences for
TLRs and cytokine-activated transcription factors, such as NFB, AP-1, and Sp1 among others, in the HIV-1 LTR promoter
has been shown, which suggests that inflammatory responses
against pathogens triggered by TLR engagement will enhance
HIV-1 exacerbation (14, 43, 63). Using the specific chemical
inhibitor BAY 11-7082, we showed that NF-B appears to be
critically necessary for F. nucleatum- and P. gingivalis-induced
HIV-1 reactivation. These results add more weight to the role
of NF-B as a positive regulator of HIV-1 reactivation that has
particularly been related to heterodimers p50/p65 in monocytic
cells (38). Of note, in spite of an increase in IL-8 production
upon TLR2 or TLR4 activation by purified agonists, an event
that involves NF-B activation, there were no changes in the
HIV-1 promoter response in monocytes/macrophages. These
results suggest that activation of certain transcription factors
(e.g., NF-B, AP-1, etc.) which also have the ability to activate
the HIV-1 promoter may not be sufficient to trigger HIV-1
reactivation as previously suggested (57). Importantly, it has
been demonstrated recently that the kinetic of NF-B activation is critical in controlling the magnitude of TLR-mediated
cytokine production (8), an event that could also play a role in
TLR-induced HIV-1 promoter activation. Likewise, silencing

of the Sp1 transcription factor significantly reduced HIV-1
reactivation induced by F. nucleatum and P. gingivalis in monocytes/macrophages. The role of Sp1 in HIV-1 recrudescence is
not fully understood; although studies suggest that Sp1 and
Sp4 members of the Sp1 multigene family are transcriptional
activators of HIV-1 LTR, Sp3 appears to be a transcriptional
repressor (51). In contrast to our findings, recent evidence
showed that Sp1 could also maintain HIV-1 latency in T cells
through recruitment of histone deacetylase-1 to the HIV-1
promoter (40). Thus, the ability of cellular transcription factors
to positively or negatively regulate HIV-1 LTR transcription
could be determined by the cell type that is latently infected as
well as the magnitude and time of activation of particular
transcription factors, which could be different depending upon
the stimuli. Besides, since some HIV-1 proteins appear to
interact with host cell transcription factors modulating their
activity (3, 17, 64), it is likely that the regulatory function of
transcription factors to either enhance or inhibit viral reactivation in HIV-1 latently infected cells might be altered with
regard to uninfected cells.
An additional observation of these studies is that both periodontal pathogens induced HIV-1 reactivation in a Tat-independent manner (i.e., absence of Tat in BF24 cell model). The
transcriptional transactivator Tat is a critical HIV-1 protein
that promotes a successful elongation during transcription of
HIV-1 proviral forms (9). These findings support the idea of a
mechanism for viral promoter activation, irrespective of the
presence of Tat that has been proposed by others (65), in
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FIG. 5. TNF-␣, but not IL-1␤, produced by THP89GFP cells in response to F. nucleatum and P. gingivalis is involved in HIV-1/EGFP promoter
reactivation. THP89GFP cells (2.5 ⫻ 105/ml) were incubated 24 h with 10 g/ml of bacterial extracts either in the presence of a specific neutralizing
antibody (gray bars) or its matched isotype control (black bars). Effects of TNF-␣ (A and B) and IL-1␤ neutralization (C and D) in HIV-1/EGFP
activity induced by F. nucleatum and P. gingivalis extracts are shown. The data are representative of two independent experiments with triplicate
determinations (n ⫽ 6). Data are expressed as means ⫾ standard deviations. ⴱ, P ⬍ 0.01 compared to the results for the cells challenged with
bacteria in the presence of neutralizing antibody versus the isotype control, as determined by Student’s t test.
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which a sustained NF-B activation would be critically necessary to enhance HIV-1 promoter activity. Hence, studies to
determine the effect of viral proteins, such as Tat, in HIV-1
promoter activity induced by oral bacteria are warranted.
Overall, we demonstrated for the first time that bacteria

associated with oral and systemic chronic inflammatory disorders enhance HIV-1 reactivation in monocytes/macrophages
through TLR2 and TLR9 activation in a mechanism that appears to be transcriptionally regulated and may not require the
viral transactivator Tat. Because HIV-1⫹ patients are treated
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FIG. 6. HIV-1 reactivation induced by F. nucleatum and P. gingivalis is positively regulated by NF-B and Sp1. BF24 or THP89GFP
monocytes/macrophages were challenged with 10 g/ml of F. nucleatum or P. gingivalis extracts either in the presence or absence of different
concentrations of the specific NF-B inhibitor BAY 11-7082 dissolved in DMSO. (A) HIV-1 CAT promoter activity in BF24 cell lysates was
determined by ELISA. (B) p24 levels were determined in THP89GFP cell supernatants as described in Materials and Methods. (C) Western blot
analyses of the total cell extract from THP89GFP cells transfected individually with two different Sp1siRNAs (Sp1siRNA 5 and 2) or with an NS
siRNA as described in Materials and Methods. Detection of ␤-actin was used as a loading control. HIV-1/EGFP promoter activation (D) and viral
replication (p24 levels) (E) induced by F. nucleatum (gray bars) and P. gingivalis (black bars) in THP89GFP cells differentially transfected are
shown. The data are representative of two independent experiments with triplicate determinations (n ⫽ 6). Data are expressed as means ⫾
standard deviations. ⴱ, P ⬍ 0.01 compared to the results for the cells transfected with Sp1 siRNA or NS siRNA versus nontransfected cells, as
determined by Student’s t test.
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4. Báfica, A., C. A. Scanga, M. L. Schito, S. Hieny, and A. Sher. 2003. Cutting
edge: in vivo induction of integrated HIV-1 expression by mycobacteria is
critically dependent on Toll-like receptor 2. J. Immunol. 171:1123–1127.
5. Beutler, B. A. 2009. TLRs and innate immunity. Blood 113:1399–1407.
6. Biswas, P., B. Mantelli, F. Delfanti, M. Cota, G. Vallanti, C. de Filippi, M.
Mengozzi, E. Vicenzi, A. Lazzarin, and G. Poli. 2001. Tumor necrosis factoralpha drives HIV-1 replication in U937 cell clones and upregulates CXCR4.
Cytokine 13:55–59.
7. Blanchard, A., L. Montagnier, and M. L. Gougeon. 1997. Influence of microbial infections on the progression of HIV disease. Trends Microbiol.
5:326–331.
8. Bode, K. A., F. Schmitz, L. Vargas, K. Heeg, and A. H. Dalpke. 2009. Kinetic
of RelA activation controls magnitude of TLR-mediated IL-12p40 induction. J. Immunol. 182:2176–2184.
9. Brady, J., and F. Kashanchi. 2005. Tat gets the “green” light on transcription
initiation. Retrovirology 2:69.
10. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S.
Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, B. R. Blazar, B.
Rodriguez, L. Teixeira-Johnson, A. Landay, J. N. Martin, F. M. Hecht, L. J.
Picker, M. M. Lederman, S. G. Deeks, and D. C. Douek. 2006. Microbial
translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365–1371.
11. Brenchley, J. M., T. W. Schacker, L. E. Ruff, D. A. Price, J. H. Taylor, G. J.
Beilman, P. L. Nguyen, A. Khoruts, M. Larson, A. T. Haase, and D. C.
Douek. 2004. CD4⫹ T cell depletion during all stages of HIV disease occurs
predominantly in the gastrointestinal tract. J. Exp. Med. 200:749–759.
12. Bush, C. E., R. M. Donovan, N. P. Markowitz, P. Kvale, and L. D. Saravolatz. 1996. A study of HIV RNA viral load in AIDS patients with bacterial
pneumonia. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 13:23–26.
13. Cahill, R. J., S. Tan, G. Dougan, P. O’Gaora, D. Pickard, N. Kennea, M. H.
Sullivan, R. G. Feldman, and A. D. Edwards. 2005. Universal DNA primers
amplify bacterial DNA from human fetal membranes and link Fusobacterium nucleatum with prolonged preterm membrane rupture. Mol. Hum.
Reprod. 11:761–766.
14. Carmody, R. J., and Y. H. Chen. 2007. Nuclear factor-kappaB: activation and
regulation during Toll-like receptor signaling. Cell. Mol. Immunol. 4:31–41.
15. Chattopadhyay, A., D. J. Caplan, G. D. Slade, D. C. Shugars, H. C. Tien, and
L. L. Patton. 2005. Risk indicators for oral candidiasis and oral hairy leukoplakia in HIV-infected adults. Community Dent. Oral Epidemiol. 33:35–44.
16. Chen, A., I. C. Boulton, J. Pongoski, A. Cochrane, and S. D. Gray-Owen.
2003. Induction of HIV-1 long terminal repeat-mediated transcription by
Neisseria gonorrhoeae. AIDS 17:625–628.
17. Chun, R. F., O. J. Semmes, C. Neuveut, and K. T. Jeang. 1998. Modulation

26.

27.

28.

29.

30.

31.

32.

33.
34.

35.

36.

37.

38.

39.

40.

of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat. J. Virol. 72:2615–2629.
Coogan, M. M., J. Greenspan, and S. J. Challacombe. 2005. Oral lesions in
infection with human immunodeficiency virus. Bull. World Health Organ.
83:700–706.
Dalpke, A., J. Frank, M. Peter, and K. Heeg. 2006. Activation of Toll-like
receptor 9 by DNA from different bacterial species. Infect. Immun. 74:940–
946.
Devadas, K., N. J. Hardegen, L. M. Wahl, I. K. Hewlett, K. A. Clouse, K. M.
Yamada, and S. Dhawan. 2004. Mechanisms for macrophage-mediated
HIV-1 induction. J. Immunol. 173:6735–6744.
Ebersole, J. L., M. J. Novak, B. S. Michalowicz, J. S. Hodges, M. J. Steffen,
J. E. Ferguson, A. Diangelis, W. Buchanan, D. A. Mitchell, and P. N.
Papapanou. 2009. Systemic immune responses in pregnancy and periodontitis: relationship to pregnancy outcomes in the Obstetrics and Periodontal
Therapy (OPT) Study. J. Periodontol. 80:953–960.
Equils, O., E. Faure, L. Thomas, Y. Bulut, S. Trushin, and M. Arditi. 2001.
Bacterial lipopolysaccharide activates HIV long terminal repeat through
Toll-like receptor 4. J. Immunol. 166:2342–2347.
Equils, O., Z. Madak, C. Liu, K. S. Michelsen, Y. Bulut, and D. Lu. 2004.
Rac1 and Toll-IL-1 receptor domain-containing adapter protein mediate
Toll-like receptor 4 induction of HIV-long terminal repeat. J. Immunol.
172:7642–7646.
Ewaschuk, J. B., J. L. Backer, T. A. Churchill, F. Obermeier, D. O. Krause,
and K. L. Madsen. 2007. Surface expression of Toll-like receptor 9 is upregulated on intestinal epithelial cells in response to pathogenic bacterial
DNA. Infect. Immun. 75:2572–2579.
Felber, B. K., and G. N. Pavlakis. 1988. A quantitative bioassay for HIV-1
based on trans-activation. Science 239:184–187.
Gibson, F. C., III, T. Ukai, and C. A. Genco. 2008. Engagement of specific
innate immune signaling pathways during Porphyromonas gingivalis induced
chronic inflammation and atherosclerosis. Front. Biosci. 13:2041–2059.
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with a combination of antiretrovirals (HAART), whether or
not antiretroviral drugs ameliorate HIV-1 reactivation in latently infected cells induced by periodontal pathogens in
monocytes/macrophages remains to be determined. Finally,
even though these are in vitro studies and more basic and
additional clinical studies are necessary, we hypothesize that
the appropriate and efficient control of oral infections, including HIV-1-associated periodontal disease in HIV-1⫹ patients,
would be expected to contribute to minimizing the likelihood
of viral recrudescence, HAART failure, and AIDS progression.
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Octavio A. González, Mengtao Li, Jeffrey L. Ebersole, and Chifu B. Huang
Center for Oral Health Research, College of Dentistry, University of Kentucky, Lexington, Kentucky
Volume 17, no. 9, pages 1417–1427, 2010. Page 1417: The title should read as shown above.

1825

